Robert Allen III Sells 27,420 Shares of Invivyd (NASDAQ:IVVD) Stock

Key Points

• Insider Robert Allen III sold 27,420 shares of Invivyd stock at an average price of $0.57, resulting in a total sale of $15,629.40, which represented a 34.07% decrease in his holdings.
• Invivyd recently reported a loss of $0.12 per share, missing expectations of a $0.04 loss, with revenues of $11.79 million, falling short of analyst estimates of $23.16 million.
• Analysts have assigned a consensus rating of "Buy" for Invivyd, with price targets ranging from $3.00 to $5.00, indicating potential upside despite recent performance concerns.

Invivyd, Inc. (NASDAQ:IVVD - Get Free Report) insider Robert Allen III sold 27,420 shares of the firm's stock in a transaction that occurred on Tuesday, August 19th. The stock was sold at an average price of $0.57, for a total transaction of $15,629.40. Following the sale, the insider directly owned 53,068 shares of the company's stock, valued at approximately $30,248.76. The trade was a 34.07% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.

Invivyd Stock Performance

Shares of NASDAQ IVVD traded down $0.0101 during mid-day trading on Tuesday, hitting $0.5710. 1,690,635 shares of the stock were exchanged, compared to its average volume of 850,421. The company has a market cap of $68.60 million, a P/E ratio of -0.62 and a beta of 0.51. The stock's fifty day simple moving average is $0.75 and its two-hundred day simple moving average is $0.84. Invivyd, Inc. has a twelve month low of $0.3546 and a twelve month high of $2.74.

Invivyd (NASDAQ:IVVD - Get Free Report) last posted its quarterly earnings data on Thursday, August 14th. The company reported ($0.12) earnings per share for the quarter, missing the consensus estimate of ($0.04) by ($0.08). The firm had revenue of $11.79 million for the quarter, compared to analyst estimates of $23.16 million. Invivyd had a negative return on equity of 177.89% and a negative net margin of 238.33%. As a group, equities research analysts predict that Invivyd, Inc. will post -1.64 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms have weighed in on IVVD. HC Wainwright restated a "buy" rating and issued a $5.00 price objective on shares of Invivyd in a research report on Thursday, June 26th. D. Boral Capital lowered their price objective on shares of Invivyd from $9.00 to $3.00 and set a "buy" rating for the company in a research report on Friday. One research analyst has rated the stock with a Strong Buy rating and three have assigned a Buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of "Buy" and a consensus price target of $3.85.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. Barclays PLC lifted its position in Invivyd by 7.8% during the 4th quarter. Barclays PLC now owns 127,180 shares of the company's stock valued at $56,000 after purchasing an additional 9,207 shares during the period. Invesco Ltd. lifted its position in Invivyd by 25.5% during the 2nd quarter. Invesco Ltd. now owns 136,755 shares of the company's stock valued at $98,000 after purchasing an additional 27,756 shares during the period. Vanguard Personalized Indexing Management LLC increased its holdings in Invivyd by 238.6% in the second quarter. Vanguard Personalized Indexing Management LLC now owns 39,941 shares of the company's stock valued at $29,000 after purchasing an additional 28,146 shares during the last quarter. Catalyst Funds Management Pty Ltd bought a new stake in Invivyd in the second quarter valued at about $27,000. Finally, 683 Capital Management LLC increased its holdings in Invivyd by 2.3% in the second quarter. 683 Capital Management LLC now owns 3,070,000 shares of the company's stock valued at $2,195,000 after purchasing an additional 70,000 shares during the last quarter. 70.36% of the stock is currently owned by institutional investors and hedge funds.

Invivyd Company Profile

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.